Such therapies are now working in a variety of animal experiments and are on the horizon for most major human brain diseases, including cerebral palsy, mental retardation, strokes, tumors, head trauma, spinal cord injury, multiple sclerosis, Lou Gehrig's disease, Alzheimer's disease, Parkinson's disease and scores of less well known neurological defects.
Importantly, this unified mutation database for the major neurodegenerative brain diseases will better accommodate the clinicogenetic overlaps between PD, AD, and FTLD.
Recent findings have directly linked major brain development, mechanisms, and diseases to the mechanical response of the brain both at the cellular and tissue levels.
Yet, in parallel to these efforts, recent findings suggest that major brain development mechanisms and diseases are directly linked to the mechanical response of the brain.
The inter-disease comparison of functional processes showed the involvement of a few major biological processes indicating that brain diseases of diverse aetiologies might utilize common biological pathways in the nervous system, without necessarily involving similar molecules.
Delivery of diagnostic or therapeutic agents across the blood-brain barrier (BBB) remains a major challenge of brain disease treatment.
The predicted target gene of miR-16-5p was CLU that could clear of beta amyloid peptide, which was one of the major brain lesions with Alzheimer's disease [ 36– 36].
This possibility may carry important implications for SC therapy, currently tested for repairing bone, curing cardiovascular diseases and targeting major brain disorders [ 20- 22].
Among the various brain diseases, ischemic stroke is considered to be a major cause behind death and disability in the developed countries.
These mAbs may provide useful tools for delineation of the expression and function of the major brain gangliosides and for probing the pathology of anti-ganglioside autoimmune diseases.
